Trial Profile
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2021 The previous primary endpoint of Objective clinical response has been replaced by 3 new primary end-points, comprising 2 for efficacy and 1 for safety, thus adding "AR" as the trial focus.
- 13 Mar 2019 Status changed from recruiting to completed.
- 20 Jan 2011 New trial record